Inhibrx Biosciences, Inc.
HealthcareNASDAQ:INBX · NASDAQ Global Market
-$1.34 today
Vol 0.26M · Avg 0.43M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1752.2%
avg -128.4%
ROIC
-117.4%
avg 985.1%
ROA
-95.6%
avg -5.5%
Analysis
ROA is currently the strongest return metric at -95.6% versus its period average of -5.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mark Paul Lappe | Founder, Chief Executive Officer & Chairman | $2.89M | — | 59 | $705,548.00 | 4.81% |
David Matly | President | $911,655.00 | — | 40 | $50,000.00 | 0.34% |
Kelly Devine Deck | Executive Vice President, Chief Financial Officer & Treasurer | $766,410.00 | — | 46 | $15,000.00 | 0.10% |
Carlos Bais | EVice President & Chief Scientific Officer | — | — | — | — | — |
Josep Garcia | Executive Vice President & Chief Clinical Development Officer | — | — | — | — | — |
Ashraf Amanullah | Executive Vice President & Chief Technical Operations Officer | — | — | 58 | — | — |
Bonne Adams | Vice President of Operations | — | — | 49 | — | — |
Leah Pollema | Vice President, General Counsel & Corporate Secretary | — | — | — | — | — |
Kate Burke | Vice President of Accounting | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$11.29M
Net Sentiment
$11.29M
Net selling
Most Active
VIKING GLOBAL INVESTORS LP
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $11.29M over the last 12 months. That adds up to net selling of $11.29M. VIKING GLOBAL INVESTORS LP was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +17.2% | +39.3% (10yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +17.2% over three years. Forward estimates point to Revenue at +39.3% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.81B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Atai Beckley Inc.
NASDAQ:ATAI
$1.44B
Immatics N.V.
NASDAQ:IMTX
$1.26B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.21B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
CureVac N.V.
CVAC
$1.05B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Who manages INBX?
Inhibrx Biosciences, Inc. (INBX) lists 9 active executives. The top listed executive is Carlos Bais, EVice President & Chief Scientific Officer.
Are INBX insiders buying or selling?
Recent insider activity shows net selling of $11.87M.
Explore More
Continue the stock analysis
Jump to another research area for this company.